Class of Stock [Axis]
Common shares, no par value
Warrants to purchase common shares, no par value
Warrants To Purchase Common Shares No Par Value One [Member]
Equity Components [Axis]
Common Stock [Member]
Additional Paid-in Capital [Member]
Warrant [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Investment, Name [Axis]
BriaPro Therapeutics Corp, [Member]
Lender Name [Axis]
Briacell Therapeutics [Member]
BC Therapeutics Inc [Member]
Related and Nonrelated Parties [Axis]
Individual Counterparty [Member]
Long-Lived Asset, Class [Axis]
Laboratory Equipment [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Share Purchase Agreement [Member]
Legal Entity [Axis]
BC Therapeutics Inc [Member]
Award Type [Axis]
Two Options [Member]
First Option [Member]
Second Option [Member]
Third Option [Member]
Business Combination [Axis]
Intangible Asset, Finite-Lived, Class [Axis]
Patents [Member]
Class of Warrant or Right [Axis]
Briacell Legacy Warrants [Member]
Briacell Shares [Member]
Bria Pro Shares [Member]
Office and Lab Space [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Statistical Measurement [Axis]
Minimum [Member]
Maximum [Member]
Asset Class [Axis]
Short-Term Investments [Member]
Fair Value, Inputs, Level 3 [Member]
Liability Class [Axis]
Warrants Liability [Member]
Sale of Stock [Axis]
September 2024 Offering [Member]
Placement Agent Warrants [Member]
Broker Warrants [Member]
Measurement Input Type [Axis]
Measurement Input, Share Price [Member]
Measurement Input, Exercise Price [Member]
Measurement Input, Expected Term [Member]
Measurement Input, Price Volatility [Member]
Measurement Input, Expected Dividend Rate [Member]
Measurement Input, Risk Free Interest Rate [Member]
Measurement Input Non Marketability Discount [Member]
October 2024 Offering [Member]
October 2024 Warrants [Member]
October 2024 Warrant [Member]
December 2024 Offering [Member]
December 2024 Warrants [Member]
Agent Warrants [Member]
December 2024 Warrant [Member]
February 2024 Offering [Member]
April 2025 Offering [Member]
Regular Warrants [Member]
April 2025 Offering [Member]
Pre Funded Warrant [Member]
April 2025 Warrants [Member]
Representative Warrants [Member]
July 2025 Offering [Member]
Prefunded Warrants [Member]
July 2025 Warrants [Member]
October 2024 Warrants [Member]
January 2026 Offering [Member]
Measurement Input, Annualized Volatility [Member]
June 2026 Offering [Member]
Share Purchase Warrants [Member]
Compensation Warrants [Member]
Share Purchase Warrants One [Member]
Share Purchase Warrants Two [Member]
Share Purchase Warrants Three [Member]
Compensation Warrants One [Member]
Compensation Warrants Two [Member]
Compensation Warrants Three [Member]
Compensation Warrants Four [Member]
Warrant One [Member]
Warrant Two [Member]
Warrant Three [Member]
Warrant Four [Member]
Warrant Five [Member]
Warrant Six [Member]
Warrant Seven [Member]
Warrant Eight [Member]
Financial Instrument [Axis]
Bria Cell Warrant [Member]
Bria Pro Warrant [Member]
Plan Name [Axis]
Stock Option Plan [Member]
BriaPro Options [Member]
Employee Stock [Member]
Exercise Price Range [Axis]
Exercise Price 5.59 [Member]
Exercise Price 12.50 [Member]
Exercise Price 60.00 [Member]
Exercise Price 904.50 [Member]
Exercise Price 1074.00 [Member]
Exercise Price 896.00 [Member]
Exercise Price 706.50 [Member]
Exercise Price 1126.50 [Member]
Exercise Price 1270.50 [Member]
Exercise Price 1060.66 [Member]
Exercise Price 0.0933 [Member]
Exercise Price 0.1108 [Member]
Exercise Price 0.0984 [Member]
Exercise Price 0.0729 [Member]
Exercise Price 0.1162 [Member]
Exercise Price 0.1310 [Member]
Exercise Price 0.1165 [Member]
Restricted Stock Units (RSUs) [Member]
Title and Position [Axis]
Director [Member]
Performance Shares [Member]
Officer [Member]
Chief Financial Officer [Member]
Chief Executive Officer [Member]
Chief Medical Officer [Member]
Chief Scientific Officer [Member]
Statement Of Income Location [Axis]
Research and Development Expenses [Member]
General and Administrative Expenses [Member]
Allocated Share Based Compensation Expenses [Member]
Related Party [Member]
Consolidated Entities [Axis]
National Cancer Institute [Member]
License Agreement [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Memorial Sloan Kettering Cancer Center [Member]
Statement [Table]
Statement [Line Items]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Document Financial Statement Error Correction [Flag]
ICFR Auditor Attestation Flag
Auditor Firm ID
Auditor Name
Auditor Opinion [Text Block]
Auditor Location
Statement of Financial Position [Abstract]
ASSETS
CURRENT ASSETS:
Cash and cash equivalents
Short-term investments
Amounts receivable and prepaid expenses
Total current assets
NON-CURRENT ASSETS:
Equity investment in BC Therapeutics
Intangible assets, net
Property and equipment, net
Long term prepaid expenses
Total non-current assets
Total assets
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Trade payables
Accrued expenses and other payables
Total current liabilities
NON-CURRENT LIABILITIES:
Warrant liability
Total non-current liabilities
CONTINGENT LIABILITIES AND COMMITMENTS
SHAREHOLDERS’ EQUITY (DEFICIT):
Share Capital of no par value – Authorized: unlimited at July 31, 2026 and 2025; Issued and outstanding: 8,708,029 and 1,883,906 shares at July 31, 2026 and 2025, respectively
Share-based payment reserve
Warrant reserve
Accumulated other comprehensive loss
Non-controlling interest
Accumulated deficit
Total shareholders’ equity
Total liabilities and shareholders’ equity
Common stock, no par value
Common stock, shares authorized unlimited
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Operating expenses:
Research, development, and clinical trial expenses, net
General and administrative expenses
Total operating expenses
Operating loss
Financial income (expenses), net
Change in fair value of the warrant liability
Unrealized gain on short-term investment
Share of loss on equity investment
Net loss for the year
Net loss attributable to non-controlling interest
Net loss for the year attributable to BriaCell
Net loss per share attributable to BriaCell - basic
Net loss per share attributable to BriaCell - diluted
Weighted average number of shares used in computing net basic earnings per share of common shares
Weighted average number of shares used in computing net diluted earnings per share of common shares
Balance
Balance, shares
Issuance of options and RSU’s
Exercise of prefunded warrants
Exercise of prefunded warrants, shares
Exercise of warrants
Exercise of warrants, shares
Issuance of units, net of issuance expenses
Issuance of units, net of issuance expenses, shares
RSU’s Exercised
RSU's Exercised, shares
Net loss for the year
Issuance of shares on settlement of PSUs
Issuance of shares on settlement of PSUs, shares
Change in ownership of BriaPro
Balance
Balance, shares
Statement of Stockholders' Equity [Abstract]
Shares issuance expenses
Statement of Cash Flows [Abstract]
Cash flow from operating activities:
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization
Financial income, net
Depreciation
Share-based compensation
Share of loss on equity investment
Change in fair value of warrants
Unrealized gain on BC Therapeutics investment
Changes in working capital:
Decrease (increase) in amounts receivable
Decrease (increase) in prepaid expenses
(Decrease) increase in accounts payable
Increase (decrease) in accrued expenses and other payables
Net cash used in operating activities
Cash flow from investing activities:
Purchase of property and equipment
Purchase of short-term investments, net
Proceeds from short-term investments
Equity investment in BC Therapeutics
Net cash used in investing activities
Cash flow from financing activities:
Proceeds from exercise of warrants
Proceeds from issuance of shares, net of issuance costs ($2,894,567 and $6,277,240, respectively)
Net cash provided by financing activities
Increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Issuance costs
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Cybersecurity Risk Management, Strategy, and Governance [Abstract]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
Cybersecurity Risk Management Processes Integrated [Flag]
Cybersecurity Risk Management Processes Integrated [Text Block]
Cybersecurity Risk Management Third Party Engaged [Flag]
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]
Cybersecurity Risk Board of Directors Oversight [Text Block]
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]
Cybersecurity Risk Role of Management [Text Block]
Cybersecurity Risk Management Positions or Committees Responsible [Flag]
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]
Material Cybersecurity Incident [Abstract]
Material Cybersecurity Incident Nature [Text Block]
Material Cybersecurity Incident Scope [Text Block]
Material Cybersecurity Incident Timing [Text Block]
Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]
Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL AND GOING CONCERN
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES
Receivables [Abstract]
AMOUNTS RECEIVABLE AND PREPAID EXPENSES
Investments, All Other Investments [Abstract]
INVESTMENT IN BC THERAPEUTICS INC
Intangible Asset, Goodwill and Other [Abstract]
INTANGIBLE ASSETS, NET
Property, Plant, and Equipment [Abstract]
PROPERTY AND EQUIPMENT, NET
Commitments and Contingencies Disclosure [Abstract]
CONTINGENT LIABILITIES AND COMMITMENTS
Short-term Investments And Fair Value Measurements
SHORT-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS
Equity [Abstract]
SHAREHOLDERS’ EQUITY
Share-Based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION
Income Tax Disclosure [Abstract]
TAXES ON INCOME
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS AND BALANCES
Financial Income Net
FINANCIAL INCOME, NET
Research and Development [Abstract]
RESEARCH, DEVELOPMENT, AND CLINICAL TRIAL EXPENSES, NET
General And Administrative Expenses
GENERAL AND ADMINISTRATIVE EXPENSES
Earnings Per Share [Abstract]
BASIC AND DILUTED NET LOSS PER SHARE
Subsequent Events [Abstract]
SUBSEQUENT EVENTS
Basis of presentation of the financial statements
Use of estimates, assumptions and judgements
Principles of consolidation
Consolidated financial statements in U.S dollars
Cash and cash equivalents
Short-term investments
Equity method investments
Property and Equipment, net
Intangible assets, net
Research and Development expenses
Fair value of financial instruments
Leases
Share-based compensation
Income Taxes
Basic and diluted net loss per Share
Segment reporting
Recently issued and adopted accounting standards
SCHEDULE OF ESTIMATED USEFUL LIVES OF ASSETS
SCHEDULE OF USEFUL LIVES OF INTANGIBLE ASSETS
SCHEDULE OF AMOUNTS RECEIVABLE AND PREPAID EXPENSES
SCHEDULE OF CHANGES IN INVESTMENT
SCHEDULE OF SHARE OF ASSETS
SCHEDULE OF INTANGIBLE ASSETS
SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSES OF INTANGIBLE ASSETS
SCHEDULE OF PROPERTY AND EQUIPMENT NET
SCHEDULE OF SHORT TERM INVESTMENT ACTIVITY
SCHEDULE OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE ON A RECURRING BASIS
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
SUMMARY OF CHANGES IN WARRANTS
SCHEDULE OF WARRANTS OUTSTANDING
SCHEDULE OF CHANGE IN FAIR VALUE OF WARRANTS
SCHEDULE OF VALUATION OF NON PUBLIC OFFERING BROKER WARRANTS
SCHEDULE OF VALUATION OF WARRANTS
Defined Benefit Plan [Table]
Defined Benefit Plan Disclosure [Line Items]
SCHEDULE OF NUMBER OF OPTIONS GRANTED
SCHEDULE OF FAIR VALUE MEASUREMENT OF EQUITY - SETTLED SHARE OPTIONS
SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS
SCHEDULE OF RESTRICTED STOCK UNITS GRANTED
SCHEDULE OF BRIAPRO RESTRICTED STOCK UNITS GRANTED
SCHEDULE OF PERFORMANCE SHARE UNITS GRANTED
SCHEDULE OF SHARE-BASED COMPENSATION EXPENSES
SCHEDULE OF LOSS BEFORE TAXES ON INCOME
SCHEDULE OF EFFECTIVE INCOME TAX
SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE AND THE EFFECTIVE INCOME TAX RATE
SCHEDULE OF DEFERRED TAX ASSETS NET
SCHEDULE OF RELATED PARTY BALANCES
SCHEDULE OF FINANCIAL INCOME (EXPENSES), NET
SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES
SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE
GeneralAndGoingConcernTable [Table]
Accumulated deficit
Cash flows from operating activities
Gross proceeds from equity
Ownership percentage
Fund for research and development
Number of shares issued
Goodwill, Reporting Unit, Number
AccountingPoliciesTable [Table]
Investment equity method percentage
Cash and cash equivalents held with non-banking financial institution
Property and equipment, net
Number of reportable segment
Property, Plant, and Equipment [Table]
Property, Plant, and Equipment [Line Items]
Estimated useful life
Useful life
Amortization method
In-house development or purchase
Prepaid Expense, Current [Abstract]
Directors and officers insurance
Prepaid expense
Other prepaids and account receivable
Amounts receivable and prepaid expenses
Prepaid expense non current
InvestmentsAllOtherInvestmentsTable [Table]
Initial loan
Share price
Equity interest percentage
Payments to Acquire Investments
Fair Value, Option, Changes in Fair Value, Gain (Loss)
Exercise price
Dividend yield
Risk free interest rate
Volatility
Options exercised, shares
Options exercised, value
Restructuring Cost [Table]
Restructuring Cost and Reserve [Line Items]
Beginning balance
Funding
BC Therapeutics Option
Change in fair value during the period
Share of losses
Ending balance
Current assets: Cash
Net assets
Patents
Gross intangible assets
Less – accumulated amortization
Intangible assets, net
2027
2028
2029
2030
2031 and thereafter
Intangible Asset, Finite-Lived [Table]
Intangible Asset, Finite-Lived [Line Items]
Amortization period
Amortization expenses
As of August 1, 2025
Additions
Disposals
As of July 31, 2026
Accumulated depreciation, beginning balance
Depreciation
Accumulated depreciation, ending balance
Net book value
Purchase of laboratory equipment
Warrant exercisable shares
Warrants are exercisable into shares
Warrants exercisable into shares
Operating lease payments
Contractual commitments
Schedule Of Short Term Investment Activity
Balance, beginning of year
Purchases of short-term investments
Proceeds from short-term investments
Unrealized gain on short-term investments
Balance, end of year
Total assets measured at fair value
Total liabilities measured at fair value
unrealized gains on short-term investments
Interest rate on investment percentage
Number of warrants outstanding, beginning balance
Weighted average exercise price, beginning balance
Number of warrants outstanding, exercised
Weighted average exercise price, exercised
Number of warrants outstanding, granted
Weighted average exercise price, granted
Number of warrants outstanding, expired
Weighted average exercise price, expired
Number of warrants outstanding, ending balance
Weighted average exercise price, ending balance
Number of warrants outstanding
Exercise price
Number of warrants exercisable
Expiry date
Warrant liability, beginning balance
Change in fair value during the period
Warrant liability, ending balance
Warrant Liability
Business Combination [Table]
Business Combination [Line Items]
Measurement input
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]
Subsidiary, Sale of Stock [Line Items]
Common stock, shares authorized
Reverse stock split
Purchase and sale of common shares
Offering price
Gross proceeds from common shares
Number of warrant shares
Exercise price of warrants
Warrants term
Fair value adjustment of warrants
Warrants and rights outstanding, measurement input
Number of warrant issued
Gross proceeds from warrant
Warrant issued
Gross proceeds from common shares
Alllocated to share capital
Description of warrants traded
Cashless exercise
Nominal exercise price per share
Other than nominal exercise price per share
Proceeds from Issuance of Private Placement
Issuance of units, shares
Warrants outstanding
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options, beginning balance
Weighted average exercise price, beginning balance
Weighted average remaining contractual term (in years)
Aggregate intrinsic value, beginning balance
Number of options, granted
Weighted average exercise price, granted
Weighted average remaining contractual term (in years), granted
Aggregate intrinsic value, Granted
Number of options, forfeited
Weighted average exercise price, granted
Number of options, expired
Weighted average exercise price, expired
Number of options, ending balance
Weighted average exercise price, ending balance
Aggregate intrinsic value, ending balance
Number of options, exercisable
Weighted average exercise price, exercisable
Weighted average remaining contractual term (in years), exercisable
Aggregate intrinsic value, exercisable
Number of options granted
Options vest periods
options expire date
Number of options issued
Expected volatility
Expected term
Weighted-average grant date per-share
Unrecognized costs
Expected volatility of the share prices
Risk-free interest rate
Expected term (in years)
Share-Based Payment Arrangement, Option, Exercise Price Range [Table]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price
Options outstanding
Weighted average remaining contractual term (years)
Options exercisable
Expiry date
Number of RSU's outstanding, beginning balance
Aggregate intrinsic value, beginning balance
Number of RSU's outstanding, granted
Aggregate intrinsic value, granted
Number of RSU's outstanding, ending balance
Aggregate intrinsic value, ending balance
RSU's, granted
Number of options granted
Grant-date fair value
Number of PSU's outstanding, granted
Number of PSU's outstanding, settled
Grant date fair value
Granted shares
Fair value of PSU's
PSUs grant date fair value
Number of PSU's outstanding,settled
CompensationRelatedCostsSharebasedPaymentsTable [Table]
StatementOfIncomeLocationAxis [Axis]
Total share-based compensation
Acquiring percentage of issued and outstanding of common stock
Options issued and outstanding
Domestic
Foreign
Loss before taxes on income
Net loss before recovery of income taxes
Expected income tax (recovery) expense
Tax rate changes and effect of taxes of subsidiaries at foreign rates
Share-based compensation and other non-deductible expenses
Share issuance costs booked directly to equity
Adjustments in respect of prior periods
R&D credits
Valuation allowance
Income tax (recovery)
Expected Income Tax (Recovery) Expense - Federal
Tax Jurisdiction of Domicile [Extensible Enumeration]
Expected Income Tax (Recovery) Expense - Federal, Percent
Canadian Provincial Tax Net of Federal Income Tax Effect
Canadian Provincial Tax Net of Federal Income Tax Effect, Percent
Foreign tax effects
Foreign tax effectsl, Percent
Research and development credit
Research and development credit, Percent
Changes in valuation allowances
Changes in valuation allowances, Percent
Share-based compensation and other nondeductible expenses
Share-based compensation and other nondeductible expenses, Percent
Share issuance costs recorded directly in equity
Share issuance costs recorded directly in equity, Percent
Adjustments in respect of prior periods
Adjustments in respect of prior periods, Percent
Changes in unrecognized tax benefits
Changes in unrecognized tax benefits, Percent
Income tax recovery and effective income tax rate, Percent
Property and equipment
Marketable securities
Intellectual property
Warrant liability
Share issuance costs
Investment in BC Therapeutics
Operating tax losses carried forward
Operating tax losses carried forward - USA
Research and development
Total deferred tax assets
Valuation allowance
Net deferred tax assets
Warrant liability
Intellectual property
Property, plant, and equipment
Total net deferred tax liabilities
Net deferred tax assets (liabilities)
Statutory income tax rate
Income tax expenses
Net operating loss carryforwards
Operating loss carryforwards in U.S. expiration year
Net operating loss carryforwards, canadian
Related Party Transaction [Table]
Related Party Transaction [Line Items]
Due from related party
Related party, balance
Schedule Of Financial Income Expenses Net
Interest income
Interest expense
Foreign exchange loss
Financial income, net
ResearchAndDevelopmentTable [Table]
Grant received from NCI
Additional grants receivable
Schedule Of General And Administrative Expenses
Wages and salaries
Professional fees and consulting
Insurance
Regulatory, filing and transfer agent fees
Shareholder communications
Share-based compensation
Other general and administrative expenses
Total general and administrative expenses
Net loss available to shareholders of ordinary shares
Shares used in computing net loss per ordinary shares, basic
Shares used in computing net loss per ordinary shares, diluted
Subsequent Event [Table]
Subsequent Event [Line Items]
Number of shares issued
License maintenance fee
Warrants to purchase common shares, no par value.
Common shares, no par value.
Warrants To Purchase Common Shares No Par Value One [Member]
Accounts receivable and prepaid expenses current.
Share-based payment reserve.
Warrant reserve.
Stock issued during period value exercise of prefunded warrants.
Stock issued during period shares exercise of prefunded warrants.
Stock issued during period value restricted stock units exercised.
Stock issued during period shares restricted stock units exercised.
Short Term Investment And Fair Value Measurements Disclosure [Text Block]
BriaPro Therapeutics Corp, [Member]
Schedule Of Estimated Useful Life Of Asset [Table Text Block]
Laboratory Equipment [Member]
Financial income net.
Schedule Of Finite Lived Intangible Assets Useful Life [Table Text Block]
Finite lived intangible assets in house development or purchase
Directors and officers insurance.
National Cancer Institute [Member]
Share Purchase Agreement [Member]
BC Therapeutics Inc [Member]
General And Administrative Expenses [Text Block]
Schedule Of General And Administrative Expenses [Table Text Block]
Two Options [Member]
First Option [Member]
Second Option [Member]
License Agreement [Member]
Memorial Sloan Kettering Cancer Center [Member]
Schedule Of Accounts Receivable And Prepaid Expenses [Table Text Block]
Gain loss on derivative instruments not designated as hedging instruments.
Finite lived intangible assets amortization expense after year four.
Regulatory filing and transfer agent fees.
Briacell Legacy Warrants [Member]
Briacell Shares [Member]
Bria Pro Shares [Member]
Office and Lab Space [Member]
Warrants Liability [Member]
IncomeTax taxreconciliation reconciliationnondeductible nondeductibleexpense expenseshare shareissuance issuancecost costbooked bookeddirectly directlyto toequity.
Income taxreconciliation reconciliationnondeductible nondeductibleexpense expenseadjustments adjustments adjustmentsin inrespect respectof ofprior priorperiods.
IncomeTax taxreconciliation reconciliationnondeductible nondeductibleexpense expenseresearch researchand anddevelopment developmentcredits.
Interest rate on investment percentage.
Deferred tax assets marketable securities
Deferred tax assets intellectual property.
Deferred tax assets warrant liability
Deferred tax liabilities warrant liability.
Deferred tax liabilities intellectual property.
Operating loss carryforwards domestic expiration year.
Effective income tax rate reconciliation change changein inunrecognized unrecognizedtax taxbenefits benefitsamount.
September 2024 Offering [Member]
Broker Warrants [Member]
Measurement Input Non Marketability Discount [Member]
October 2024 Offering [Member]
October 2024 Warrants [Member]
Placement Agent Warrants [Member]
October 2024 Warrant [Member]
December 2024 Offering [Member]
Effective income tax rate reconciliation change changein inunrecognized unrecognizedtax taxbenefits benefitspercentage.
December 2024 Warrants [Member]
December 2024 Warrant [Member]
Schedule Of Effective Statutory Income Tax Rate Reconciliation [Table Text Block]
February 2024 Offering [Member]
April 2025 Offering [Member]
Regular Warrants [Member]
Acquiring percentage of issued and outstanding of common stock.
Stock Option Plan [Member]
Description of warrants traded.
April 2025 Offering [Member]
April 2025 Warrants [Member]
July 2025 Offering [Member]
Prefunded Warrants [Member]
July 2025 Warrants [Member]
Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual granted.
October 2024 Warrants [Member]
January 2026 Offering [Member]
Nominal exercise price per share
Other than nominal exercise price per share
Share based compensation arrangement by share based payment award options grants in period granted intrinsic value.
Measurement Input, Annualized Volatility [Member]
June 2026 Offering [Member]
Exercise Price 60.00 [Member]
Exercise Price 904.50 [Member]
Exercise Price 1074.00 [Member]
Exercise Price 706.50 [Member]
Exercise Price 1126.50 [Member]
Exercise Price 1270.50 [Member]
Exercise Price 1060.66 [Member]
Exercise Price 896.00 [Member]
Exercise Price 5.59 [Member]
Exercise Price 12.50 [Member]
Agent Warrants [Member]
Share Purchase Warrants [Member]
Sharebased compensation arrangement by sharebased payment award nonoption equity instruments outstanding weighted average exercise price.
Sharebased compensation arrangement by sharebased payment award nonoption equity instruments weighted average exercise price expired.
Sharebased compensation arrangement by sharebased payment award nonoption equity instruments weighted average exercise price granted.
Share Purchase Warrants One [Member]
Share Purchase Warrants Two [Member]
Share Purchase Warrants Three [Member]
Sharebased compensation arrangement by sharebased payment award nonoption equity instruments weighted average exercise price exercised.
BriaPro Options [Member]
Exercise Price Zero Point Zero Nine Three Three [Member]
Exercise Price Zero Point One One Zero Eight [Member]
Exercise Price Zero Point Zero Nine Eight Four [Member]
Exercise Price Zero Point Zero Seven Two Nine [Member]
Exercise Price Zero Point One One Six Two [Member]
Warrant One [Member]
Warrant Two [Member]
Exercise Price Zero Point One Three One Zero [Member]
Warrant Three [Member]
Exercise Price Zero Point One One Six Five [Member]
Warrant Four [Member]
Warrant Five [Member]
Warrant Six [Member]
Warrant Seven [Member]
Share based compensation arrangement by share based payment award equity instruments other than options aggregate intrinsic value outstanding granted.
Compensation Warrants [Member]
Schedule Of Share Based Compensation Expenses [TableTextBlock]
Share based compensation arrangement by share based payment award equity instruments other than options settled in period.
Compensation Warrants One [Member]
Compensation Warrants Two [Member]
Compensation Warrants Three [Member]
Compensation Warrants Four [Member]
Chief Scientific Officer [Member]
Chief Medical Officer [Member]
Warrant Eight [Member]
Schedule Of Changes In Fair Value Of Warrants [Table Text Block]
Schedule Of Non Public Warrant [Table Text Block]
Schedule Of Warrant Valiuation Input [Table Text Block]
Bria Pro Warrant [Member]
Bria Cell Warrant [Member]
Unrealized gain on short-term investment.
Briacell Therapeutics [Member]
Third Option [Member]
Exercise of warrants, value.
Exercise of warrants, shares.
Issuance of shares on settlement of PSUs, value.
Issuance of shares on settlement of PSUs, shares.
Shares issuance expenses.
Stock issued during period value performance shares award gross.
Canadian Provincial Tax Net of Federal Income Tax Effect.
Canadian Provincial Tax Net of Federal Income Tax Effect, Percent.
Income tax reconciliation share issuance costs recorded directly in equity.
Effective Income tax rate reconciliation share issuance costs recorded directly in equity.
Financial Income Expenses Disclosure [Text Block]
Schedule of Financial Income [Table Text Block]
Shareholder communications.
Representative Warrants [Member]
Effective income tax rate reconciliation tax credits research and development credit.
Currency [Policy Text Block]
Stock issued during period shares warrants exercised.
Cash and cash equivalents held with non-banking financial institution.
BC Therapeutics Inc [Member]
Effective income tax rate reconciliation at federal and provincial statutory income tax rate.
Other prepaids and account receivable current.
Statement of Income Location Axis
Research and Development Expenses [Member]
General and Administrative Expenses [Member]
Allocated Share Based Compensation Expenses [Member]
Fair value adjustment of warrant.
BC Therapeutics Inc [Member] [Default Label]
April 2025 Offering [Member] [Default Label]
October 2024 Warrants [Member] [Default Label]
Assets, Current
Assets, Noncurrent
Assets
Liabilities, Current
Liabilities, Noncurrent
Equity, Including Portion Attributable to Noncontrolling Interest
Liabilities and Equity
Operating Expenses
Operating Income (Loss)
Shares, Outstanding
FinancialIncomeNet
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Prepaid Expense
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Payments to Acquire Property, Plant, and Equipment
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
Commitments and Contingencies Disclosure [Text Block]
Cash and Cash Equivalents, Policy [Policy Text Block]
Investment, Policy [Policy Text Block]
Intangible Assets, Finite-Lived, Policy [Policy Text Block]
Share-Based Payment Arrangement [Policy Text Block]
Property, Plant, and Equipment, before Accumulated Depreciation, Depletion, and Amortization
Equity Method Investments
Net Assets
Intangible Asset, Finite-Lived, before Accumulated Amortization
Intangible Asset, Finite-Lived, Accumulated Amortization
Intangible Asset, Finite-Lived, after Accumulated Amortization
Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization
Depreciation, Depletion and Amortization
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInPeriod
Income (Loss) from Continuing Operations before Income Taxes, Domestic
Income (Loss) from Continuing Operations before Income Taxes, Foreign
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCredits
Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
Effective Income Tax Rate Reconciliation, Percent
DeferredTaxAssetsWarrantLiability
Deferred Tax Assets, Gross
Deferred Tax Assets, Valuation Allowance
Deferred Tax Assets, Net of Valuation Allowance
DeferredTaxLiabilitiesWarrantLiability
DeferredTaxLiabilitiesIntellectualProperty
Deferred Tax Liabilities, Property, Plant and Equipment
Deferred Tax Liabilities, Gross
Deferred Tax Assets, Net
Interest Expense, Nonoperating
Share-Based Payment Arrangement, Noncash Expense